France
Cure51, founded in 2021, is a TechBio startup revolutionizing cancer research through its pioneering global database of Cancer Survivors with the mission: “We want every patient to become a Cancer Survivor.” Founded in collaboration with leading oncology centers, Cure51 has identified over 1,500 survivors across 42 countries.
The French-based company stands out for its proprietary data collection and discovery platform, enhanced by a dedicated Central Lab for multiomic sequencing of survivor samples. This meticulous approach aims to uncover robust therapeutic targets, validated by a reputable scientific community, to introduce groundbreaking cancer drugs.
Cure51 initially targets three aggressive cancer types, with plans to expand across more indications, leveraging its unique data and discovery pipelines. In March 2024, the company secured a €15.00M seed investment from esteemed investors like Sofinnova Partners, Xavier Niel, Hitachi Ventures, LifeX, and Olivier Pomel.
